Improving lives through peptide-based clearance of p53-impaired cells.
That’s our mission
Cleara Biotech is a biopharmaceutical research and development (R&D) company focused on developing peptide-based therapies against cancer and chronic diseases. Our lead program focuses on generating compounds against cancer cells with high levels of impaired-p53 signaling, especially those with mutant p53.
Over two decades of fundamental research led to an understanding of how p53 signaling becomes impaired in cells suffering from irreparable damage. This proved to be a vulnerability that could be exploited to develop therapeutics against these diseases.
Using this proprietary knowledge, Cleara Biotech developed a disruptive, innovative platform technology to safely and selectively eliminate p53-impaired cells. This resulted in a development candidate, CL04183, which selectively induces apoptosis in cancer cells harboring impaired p53 in ways that are (1) not transcription-dependent and (2) agnostic of the mutation site.
Two lead development candidates
Cleara has optimized two lead development candidates, CL04177 and CL04183 that are specifically able to eliminate a type called “scarred” senescence, found in several chronic diseases and late-stage cancer in humans. CL04183/4177 show favorable pharmacokinetics and tissue distribution in mice and have an MTD that is well above their efficacious dose. They have very long shelf-life, plasma stability and are resistant to degradation by liver enzymes.
In 2D cells, 3D organoid and mouse in vivo models for metastatic colon cancer (mCRC) and triple-negative breast cancer (TNBC), CL04177/4183 potently counter metastatic burden and infiltration. Importantly, this is matched with the presence of biomarkers and Cleara designed a preclinical and clinical development strategy towards progressing these lead development compounds towards clinical trials in solid tumors as well as hematological malignancies.